UPDATE: Stifel Nicolaus Raises PT to $117 on Stericycle Following Solid Q4
Stifel Nicolaus reiterated its Buy rating on Stericycle (NASDAQ: SRCL) and raised the price target from $102.00 to $117.00.
Stifel Nicolaus commented, "SRCL posted another solid quarter and raised guidance again. Revenue and EPS were ahead of estimates, though FCF came in within the expected range. We believe SRCL has largely completed the platform acquisitions it was making in the Patient Communications space that were weighing on company margins (they were declining), and margins have improved in each of the last two quarters."
Stericycle closed at $95.12 on Wednesday.
Latest Ratings for SRCL
|Apr 2017||Barclays||Initiates Coverage On||Overweight|
|Mar 2017||Goldman Sachs||Upgrades||Sell||Neutral|
|Nov 2016||Goldman Sachs||Downgrades||Neutral||Sell|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.